Acute Anterior ST-Segment Elevation Myocardial Infarction
Conditions
Keywords
Acute Anterior ST-Segment Elevation Myocardial Infarction, ST-Segment Elevation Myocardial Infarction(STEMI)
Brief summary
This is a multicenter, randomized, double-blind, placebo-controlled, single-dose, Phase II clinical study to evaluate the efficacy, safety, and pharmacokinetic (PK) characteristics of SGC001 injection administered in addition to standard clinical care in Chinese patients with acute anterior ST-segment elevation myocardial infarction (STEMI) who are planned for primary percutaneous coronary intervention (pPCI).
Detailed description
The study drug will be administered intravenously within 6 hours of the onset of acute myocardial infarction symptoms, on top of standard of care. The primary efficacy endpoint is the percentage of myocardial infarction size on Day 4 post-dosing, assessed by cardiac magnetic resonance (CMR) imaging. Secondary endpoints include myocardial infarction size at Day90, microvascular obstruction area and left ventricular function parameters at Day4 and Day90, myocardial salvage index at Day4, biomarkers (hs-TnI, hs-CRP, CK-MBmass, NT-proBNP), and composite incidence of cardiovascular death or heart failure events within 90 days. Safety assessments include adverse events, serious adverse events, physical examinations, vital signs, ECGs, and laboratory tests. Participants will undergo follow-up visits at Days 30 and 90, with a telephone follow-up at Day 180 to record survival status and heart failure events.
Interventions
DRUGSGC001 injection
Dosage: 600mg single dose The administration must be completed as early as possible within 6 hours after the onset of acute myocardial infarction symptoms and before PCI reperfusion (i.e., before guidewire crossing)
DRUGPlacebo
Dosage: 0mg single dose The administration must be completed as early as possible within 6 hours after the onset of acute myocardial infarction symptoms and before PCI reperfusion (i.e., before guidewire crossing)
Sponsors
Beijing Sungen Biomedical Technology Co., Ltd
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 79 Years
Healthy volunteers
No
Inclusion criteria
1.18-79 years of age (including boundary values), male or female; 2.Anterior wall STEMI: (a) history of persistent chest pain/precordial discomfort (\>30 minutes); (b) upon admission, the ECG must meet the following requirements: i.For male participants \>40 years old, ST-segment elevation ≥2 mm in leads V2 and V3; ii.For male participants ≤40 years old, ST-segment elevation ≥2.5 mm in leads V2 and V3; iii.For female participants, ST-segment elevation ≥1.5 mm in leads V2 and V3; If clinical symptoms of (a) are atypical, then (c) a positive point-of-care troponin test is required. 3.Planned for pPCI treatment; 4.Assessed as being able to complete dosing within 6 hours of the onset of persistent chest pain/precordial discomfort symptoms; 5.The participant or their legal guardian fully understands the objectives, nature, methods, and potential adverse reactions of the study, voluntarily agrees to participate, and has signed the informed consent form (ICF).
Exclusion criteria
1. History of the following cardiac conditions: 1. History of myocardial infarction, coronary revascularization (including percutaneous coronary intervention \[PCI\] and coronary artery bypass grafting \[CABG\], etc.); 2. History of cardiopulmonary resuscitation; 3. History of stroke within 6 months; 4. Presence of severe cardiac structural abnormalities such as aortic dissection, and ventricular aneurysm; 2. Patients who have received thrombolysis; 3. Patients with a life expectancy of less than 1 year; 4. Febrile infection requiring systemic treatment within 2 weeks prior to screening; 5. Concomitant left bundle branch block; 6. Cardiogenic shock or hemodynamic instability; 7. Concomitant severe arrhythmia (including high-degree atrioventricular block, sick sinus syndrome, sustained ventricular tachycardia, etc.) or implanted cardiac pacemaker; 8. Definitive diagnosis of acute heart failure (Killip classification ≥ III; for details on Killip classification, see Appendix); 9. Unable to undergo cardiac magnetic resonance (CMR) imaging according to the study protocol, or known allergy to any radiocontrast agent;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of myocardial infarction size(ratio of infarct mass to left ventricular mass) | Day 4 post-dosing |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of myocardial infarction size | Day 90 post-dosing | — |
| Percentage of microvascular obstruction area (MVO) | Day 4 and Day 90 post-dosing | — |
| Myocardial salvage index | Day 4 post-dosing | — |
| Left ventricular ejection fraction (LVEF), left ventricular end-systolic volume index (LVESVI), and left ventricular end-diastolic volume index (LVEDVI) | Day 4 and Day 90 post-dosing | — |
| High-sensitivity troponin I (hs-TnI), high-sensitivity C-reactive protein (hs-CRP), creatine kinase-MB mass (CK-MBmass) | baseline (pre-dose), and at 1 hour, 8 hours, Day 2, Day 5, and Day 30 post-dosing | — |
| N-terminal pro-brain natriuretic peptide (NT-proBNP) | baseline (pre-dose), and at 1 hour, 8 hours, Day 2, Day 5, Day 30, Day90 post-dosing | — |
| Composite incidence of cardiovascular death or heart failure events | Within 90 days post-dosing | — |
| Incidence of cardiovascular death | Within 90 days post-dosing | — |
| Incidence of heart failure events | Within 90 days post-dosing | — |
| Safety endpoints | Within 90 days post-dosing | Adverse events (AEs)/serious adverse events (SAEs)/physical examinations/vital signs/ECGs/laboratory tests |
Countries
China
Contacts
CONTACTWei Gao, Doctor
Outcome results
None listed